Zura Bio Ltd (ZURA) - Q2 2026 10-Q Summary
Business Context and Reporting Period
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for autoimmune and inflammatory diseases. The reporting period covers the three and six months ended June 30, 2026. The Company is classified as an Emerging Growth Company and a Smaller Reporting Company. As of June 30, 2026, the Company had 95,422,452 Class A Ordinary Shares outstanding.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(26.3) million | $(16.0) million | $(50.5) million | $(33.4) million |
| Operating Expenses | $29.3 million | $18.1 million | $54.8 million | $37.3 million |
| R&D Expenses | $20.7 million | $8.7 million | $35.5 million | $19.2 million |
| G&A Expenses | $8.6 million | $9.4 million | $19.4 million | $18.1 million |
| Cash and Equivalents (End of Period) | $205.1 million | $154.5 million | $205.1 million | $154.5 million |
| Net Cash Used in Operating Activities | N/A | N/A | $(39.8) million | $(27.1) million |
| Net Cash Provided by Financing Activities | N/A | N/A | $135.6 million | $5.1 million |
Note: All figures in millions unless otherwise noted. The filing does not provide specific margin percentages as the Company has no revenue.
Material Changes vs. Prior Period
- Increased R&D Spend: Research and development expenses increased by 138% ($12.0 million) in Q2 2026 compared to Q2 2025. This was driven by the advancement of Phase 2 clinical trials for tibulizumab in Hidradenitis Suppurativa (HS) and Systemic Sclerosis (SSc), increased drug manufacturing costs, and higher personnel expenses.
- Financing Activity: In February 2026, the Company completed an equity offering raising approximately $134.6 million in net proceeds. This significantly improved liquidity, increasing cash balances from $109.4 million at year-end 2025 to $205.1 million at June 30, 2026.
- Other Income: Other income, net increased due to the receipt of a $1.0 million R&D incentive credit from the U.K. government during the quarter.
- Share Count: Outstanding shares increased from 73.7 million at December 31, 2025, to 95.4 million at June 30, 2026, primarily due to the February 2026 equity offering.
Guidance, Outlook, and Risks
- Clinical Milestones:
- TibuSHIELD (HS): Enrollment complete (247 participants). Topline results expected in Q4 2026.
- TibuSURE (SSc): Enrollment complete (91 participants). Topline results expected in H1 2027.
- Polymyalgia Rheumatica: Phase 2 trial planned for initiation by year-end 2026.
- Liquidity Outlook: Management believes existing cash and cash equivalents ($205.1 million) are sufficient to fund operations through at least the end of 2028.
- Risks and Contingencies:
- The Company has no approved products and has incurred significant losses since inception.
- Future funding requirements depend on clinical trial outcomes, regulatory approvals, and potential milestone payments to licensors (Lilly, Pfizer, Lonza, WuXi Biologics).
- Significant contingent payments exist: up to $155 million in development milestones and $440 million in sales milestones for tibulizumab (Lilly); similar structures for torudokimab and crebankitug.
- Macroeconomic factors, including geopolitical conflicts and inflation, may impact costs and timelines.
Key Facts for Investor Verification
- Cash Runway: Verify the assumption that $205.1 million in cash will sustain operations through 2028 given the accelerating R&D burn rate.
- Clinical Data: Monitor the Q4 2026 release of TibuSHIELD (HS) topline data as a critical value inflection point.
- Dilution: Note the significant increase in share count (approx. 30% increase YTD) and the existence of ~29.3 million pre-funded warrants outstanding.
- Licensing Obligations: Review the specific triggers for the $155M+ development milestones owed to Lilly and Pfizer, which could impact future cash flow upon success.
- Revenue Model: Confirm that the Company remains pre-revenue with no commercial sales expected in the near term.